Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was to evaluate the pharmacokinetics of single and multiple doses of oral lafutidine tablets and the effect of food on pharmacokinetics in healthy Chinese subjects. The tolerability and the effect of sex on the pharmacokinetic properties were also evaluated to acquire more pharmacokinetic information.
The study of single-dose was randomized, three-period, crossover. And in this study, 12 subjects were randomly assigned to 3 dose groups and received a single dose of 10mg, 20mg and 40mg lafutidine tablets. The washout period was 7 calendar days. In the multiple-dose, 12 subjects took lafutidine tablets of 10 mg twice a day for 6 consecutive days. In the food-effect study, 12 subjects were randomly assigned to 2 groups. One group received a single dose of 10mg lafutidine tablets under fasted condition, while the other were in fed condition. The drug administrations were separated by a wash-out period of seven calendar days. In each study group, the male and the female are both in half of the subjects. Using a liquid chromatography tandem mass spectrometry (LC/MS/MS) method to determine the plasma concentration of lafutidine. Pharmacokinetic parameters were calculated using the single compartment model.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 10-mg group | Experimental | Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state. |
|
| 20-mg group | Experimental | Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state. |
|
| 40-mg group | Experimental | Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| lafutidine | Drug | comparison of different doses, sex and medication conditions |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmax | Peak concentration | one day |
| Area under the curve | Area under the curve - plasma concentration | one day |
| Clearance | Clearance | one day |
| Apparent volume of distribution-V | The apparent volume of distribution | one day |
| Measure | Description | Time Frame |
|---|---|---|
| Safety (adverse events) | six weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Weiyong Li, PhD | HUST/Union Hospital | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| C076948 | lafutidine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided